—
“EpiCast Report: Venous Thromboembolism - Epidemiology Forecast To 2026” states that major drivers of the rise in market value include an increase in patient uptake of novel oral anticoagulants (NOACs), the launch of betrixaban for extended-duration prophylaxis in acute medically ill patients, and an increase in the global prevalence of VTE.Epidemiologists forecast an increase in the diagnosed incident cases of VTE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), from 896,377 cases in 2016 to 1,071,438 in 2026, at an Annual Growth Rate (AGR) of 1.95%.The number of VTE attacks is forecast to grow from 1,020,991 in 2016 to 1,224,696 in 2026 in the 7MM. Epidemiologists have identified the predominant drivers of this market to be changes in country-specific incidence and procedure rates, as well as in the underlying demographic trends.
Order a copy of this research report at https://www.marketinsightsreports.com/report/purchase/062215914?mode=su
Although the NOACs will contribute to a major growth burst in the VTE forecast, the genericization of major NOAC players in the VTE treatment and total knee replacement and total hip replacement segments will result in decreasing sales within these NOAC treated VTE patient segments.
Conversely, sales in the acute medically ill space will be given a boost through the launch of Portola Pharmaceuticals’ pipeline contender, betrixaban, which is projected to reach peak sales of $577 million by 2026, as well as Xarelto’s expected label expansion to treat this patient population.
Epidemiologists forecast the prevalent cases of VTE in the 7MM from 2016-2026 using nationally-representative, country-specific studies published in peer-reviewed journals that provided the age- and sex-specific incidence of VTE, DVT, and PE in the 7MM. Additionally, they forecast the number of VTE attacks, medically ill discharges at risk of VTE, knee and hip replacements, recurrent VTE cases at one and 10 years, and VTE cases with cancer as comorbidity. GlobalData epidemiologists ensured that the forecast methodology was consistent across all the 7MM to allow for a meaningful comparison of the diagnosed incident cases of VTE across these markets.
Complete research report of 45 pages with TOC and List of Figures is available at https://www.marketinsightsreports.com/reports/062215914/epicast-report-venous-thromboembolism-epidemiology-forecast-to-2026
Scope of this report: The Venous Thromboembolism (VTE) EpiCast Report provides an overview of the risk factors and global trends of VTE in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed incident cases of VTE, deep vein thrombosis, and pulmonary embolism segmented by sex and age (in five-year increments beginning at ages zero to four years and ending at 85 years and older) in these seven markets. Additionally, this report includes the number of VTE attacks, medically ill discharges at risk of VTE, primary total knee and hip replacements, recurrent VTE cases after one and 10 years, and diagnosed VTE cases with cancer as comorbidity. The VTE epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The VTE EpiCast report will allow you to: Develop business strategies by understanding the trends shaping and driving the global VTE market. Quantify patient populations in the global VTE market to improve product design, pricing, and launch plans. Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for VTE therapeutics in each of the markets covered. Identify the percentage of VTE cases with recurrence of VTE and percentage of VTE cases with cancer as comorbidity.
Contact Info:
Name: Diane Conrad
Email: Send Email
Organization: Market Insights Reports
Website: https://www.marketinsightsreports.com/reports/062215914/epicast-report-venous-thromboembolism-epidemiology-forecast-to-2026
Release ID: 210427
Google
RSS